Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
75°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by TScan Therapeutics, Inc.
< Previous
1
2
Next >
TScan Therapeutics to Participate in Upcoming Investor Conferences
September 05, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
August 29, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Transition of Chief Financial Officer
June 29, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
June 06, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
June 01, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Closing of Public Offering
June 01, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Pricing of $140 Million Public Offering
May 26, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Launch of Proposed Public Offering
May 25, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
May 24, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
May 17, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
May 09, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AMGN
TCRX
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 02, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
April 10, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces CEO Transition
March 31, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
March 14, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
March 13, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
March 08, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
February 21, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
January 23, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
January 05, 2023
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
December 12, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
December 01, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting
November 11, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
TScan Therapeutics Announces Upcoming Virtual Investor Event
November 07, 2022
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TCRX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.